3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
376
Neoplasm Metastasis
21
Neoplasms
11
Advanced Breast Cancer
10
Carcinoma, Intraductal, Noninfiltrating
8
Triple Negative Breast Neoplasms
7
Osteoporosis
7
Carcinoma, Ductal, Breast
7
Breast Neoplasms, Male
7
Breast Diseases
7
Breast Carcinoma In Situ
6
Carcinoma, Lobular
5
Prostatic Neoplasms
4
Hereditary Sensory and Autonomic Neuropathies
4
Breast Cancer Metastatic
4
Arthralgia
4
Recurrence
3
Ovarian Neoplasms
3
Neoplasms, Hormone-Dependent
3
Squamous Cell Carcinoma of Head and Neck
2
Pain
2
Obesity
2
Neoplasms by Site
2
Multiple Endocrine Neoplasia Type 1
2
Infertility
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Endometrial Neoplasms
2
Interventions
Cyclophosphamide
38
Paclitaxel
22
Epirubicin
21
Trastuzumab
20
Docetaxel
20
Doxorubicin
19
Carboplatin
15
Radiotherapy
13
Taxes
11
Filgrastim
11
Neoadjuvant Therapy
9
Bevacizumab
9
Fluorouracil
8
pembrolizumab
7
Tamoxifen
7
Albumin-Bound Paclitaxel
7
Capecitabine
6
pertuzumab
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Lapatinib
5
130-nm albumin-bound paclitaxel
5
pegfilgrastim
4
Granulocyte Colony-Stimulating Factor
4
Cisplatin
4
Chemotherapy, Adjuvant
4
Biopsy
4
tipifarnib
3
eribulin
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inflammatory Breast Neoplasms
×
Letrozole
×
Breast
×
Clear all
NCT02221999
2023-08-29
SHPD002
RenJi Hospital
Phase 2/3
Active not recruiting
250 enrolled